Last reviewed · How we verify
NPC-16 Standard Dosing Regimen Group
NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses.
NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | NPC-16 Standard Dosing Regimen Group |
|---|---|
| Also known as | Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg |
| Sponsor | Nobelpharma |
| Drug class | S1P receptor modulator |
| Target | S1PR1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to S1PR1, NPC-16 inhibits the egress of lymphocytes from lymphoid organs, thereby reducing inflammation and autoimmune responses. This mechanism is thought to be beneficial in treating autoimmune diseases such as multiple sclerosis.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPC-16 Standard Dosing Regimen Group CI brief — competitive landscape report
- NPC-16 Standard Dosing Regimen Group updates RSS · CI watch RSS
- Nobelpharma portfolio CI